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Abstract
Hepatocyte-like cells (HLCs) are generated from either various human pluripotent stem 
cells (hPSCs) including induced pluripotent stem cells (iPSCs) and embryonic stem cells 
(ESCs), or direct cell conversion, mesenchymal stem cells as well as other stem cells like 
gestational tissues. They provide potential cell sources for biomedical applications. Liver 
transplantation is the gold standard treatment for the patients with end stage liver disease, 
but there are many obstacles limiting this process, like insufficient number of donated 
healthy livers. Meanwhile, the number of patients receiving a liver organ transplant for 
a better life is increasing. In this regard, HLCs may provide an adequate cell source to 
overcome these shortages. New molecular engineering approaches such as CRISPR/
Cas system applying in iPSCs technology provide the basic principles of gene correction 
for monogenic inherited metabolic liver diseases, as another application of HLCs. It has 
been shown that HLCs could replace primary human hepatocytes in drug discovery and 
hepatotoxicity tests. However, generation of fully functional HLCs is still a big challenge; 
several research groups have been trying to improve current differentiation protocols to 
achieve better HLCs according to morphology and function of cells. Large-scale genera-
tion of functional HLCs in bioreactors could make a new opportunity in producing enough 
hepatocytes for treating end-stage liver patients as well as other biomedical applications 
such as drug studies. In this review, regarding the biomedical value of HLCs, we focus 
on the current and efficient approaches for generating hepatocyte-like cells in vitro and 
discuss about their applications in regenerative medicine and drug discovery. 
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Introduction
Nowadays human primary hepatocytes are 
regularly used, as the most important and efficient 
cells in the liver organ for biomedical applications, 
e.g. cell therapy and drug studies (1-3). Some 
evidences reported application of hepatocytes for 
cell therapy clinical trial of various liver disorders 
(4, 5). Although limited access to sufficient 
human functional hepatocyte, due to the lack of 
availability of healthy donors as well as difficulties 
in hepatocyte long-term maintenance, are major 
problems in using these specialized cells (6). 
Primary human hepatocytes, usually derived 
from the livers, are immunologically rejected for 
transplantation and therefore the yield and quality 
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of the isolated hepatocytes are a limiting factor 
in any biomedical application (3, 7). Researchers 
has currently introduced another source of 
hepatocyte as possible substitute, known as 
hepatocyte-like cells (HLCs), which has been 
produced in vitro. HLCs are usually derived 
from human pluripotent stem cell (hPSCs), 
including human embryonic stem cells (hESCs) 
and induced pluripotent stem cells (iPSCs), 
gestational stem cells and mesenchymal stromal 
cells. Direct cell conversion is another method 
to generate HLCs (6, 8). Protocols to generate 
higher quality of HLCs are continuously 
improving and different research groups are 
working in this regard. Moreover, scaling up 
production of HLCs, using three-dimensional 
system (3D) in bioreactors, resulted in generating 
enough cells for any biomedical application 
(9, 10). In this review, we briefly described 
different methods to produce HLCs in vitro and 
explained some of their applications in research 
and regenerative medicine. Figure 1 presents 
regenerative medicine, drug study, some sources 
and applications of HLCs.
Fig.1: Main sources of HLCs and their applications in regenerative medicine and drug discovery. Diagram of some sources of HLC (Left): 
biopsy derived fibroblasts from liver disease patient can directly be converted into HLCs, by overexpression of liver specific transcription 
factors (TFs). Patient specific iPSCs generated by overexpression of Yamanaka factors (Oct4, Sox2, Klf4 and c-Myc) can also be differentiated 
to HLCs for further applications. Embryonic stem cells from ICM of blastocyst are other sources of HLCs. 
Diagram of some potential biomedical applications of HLC (Right): HLCs can be used for patients with end-stage liver disease. In addition, 
using iPSCs technology, monogenic disorders can be corrected in metabolic liver diseases at genome level and then healthy patient 
specific iPSC-derived HLCs could be a source for transplantation and decreasing signs of the disease. Drug screening after disease 
modeling, using patient specific iPSC-derived HLCs, to achieve new drugs for specific patients and individual drug administrations are 
another application of HLCs in the personalized medicine field.
HLCs; Hepatocyte-like cells and iPSCs; Induced pluripotent stem cells.
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Different types of produced hepatocyte-like 
cells in vitro
Human embryonic stem cells-derived hepatocytese
ESCs, derived from the inner cell mass of 
blastocysts are immortalize cell type with ability to 
differentiate into all somatic cell lineages (11, 12). 
These primitive and highly undifferentiated cells 
were firstly isolated from mouse embryos (mESCs) 
(11) and the first hESCs line was successfully 
derived from in vitro fertilized human embryos (13). 
It has been shown that these cells with a high level 
of self-renewal ability and possibility to produce 
nearly all cell types, including "hepatocyte", can 
be used as an important tool for basic and clinical 
researches (14). There are two ways to produce 
HLCs through hESC: spontaneous differentiation 
and directed differentiation.
In the first approach, hESCs are aggregated to 
form human embryoid bodies (hEBs). These cell 
aggregates spontaneously start to differentiate 
into the three germ layers, including endodermal 
cells (15, 16). It has been shown that hESC can 
differentiate into hepatic-like cells through the 
EB formation, thus albumin-expressing cells have 
subsequently been detected in EBs (17, 18). Due to 
the low efficiency of spontaneous differentiation of 
hESCs, possibility of miscellaneous differentiation 
into any other cells and possibility of differentiation 
into non-homogeneous population of cells, 
scientists focused on the directed differentiation of 
hESCs into HLCs (14).
In this approach, several protocols have been 
developed to differentiate ES cells toward HLCs 
sequentially. In these protocols a series of growth 
factors and some other soluble factors which 
participate during liver development have been 
used in a stepwise manner, mimicking in vivo 
liver development (15, 19-22). Generally, these 
protocols have some specific steps. The first 
step is "Endoderm induction" whereby mainly 
activin is used. The second step is "Hepatic 
specification" using some factors like bone 
morphogenetic proteins (BMPs) and fibroblast 
growth factors (FGFs). "Hepatoblast (hepatic stem 
cell) expansion" and "Hepatic maturation" are 
respectively the other steps, developed by using 
specific growth factors like hepatocyte growth 
factor (HGF), epidermal growth factor (EGF), 
oncostatin M (OSM) and Dexamethasone (DEX) 
(8). The progress in each step is usually evaluated 
by specific markers. Bile duct cells are excluded 
based on their specific markers in order to have 
a more homogenous population of hepatocytes 
(23). Siller et al. (24) recently presented a growth-
factor-free protocol using only small molecules 
to induce HLC differentiation to pluripotent stem 
cells. CHIR99021, as potent pharmacological 
glycogen synthase kinase-3 (GSK-3)-specific 
inhibitor activating wingless-type MMTV 
integration site family (Wnt) signaling pathway 
during hepatocyte differentiation (25), was used 
to induce definitive endoderm formation, followed 
by treatment with dimethyl sulfoxide (DMSO), 
dexamethasone, hydrocortisone-21-hemisuccinate 
and Ile-(6) aminohexanoic amide (dihexa), as a 
small molecule that is an agonist of HGF (26), to 
drive hepatic maturation. The polygonal HLCs 
were generated, which expressed hepatic specific 
markers like albumin, AFP and alpha-1 antitrypsin 
(A1AT) with proper functionalities. In addition, 
some other groups have tried to improve current 
hepatic differentiation protocols with different 
strategies like using other appropriate cells for 
co-culture, monolayer culture or using 3D cell 
aggregates, through differentiation protocols (9, 
27-31).
Induced pluripotent stem cells-derived hepatocytes
HLCs can be efficiently produced by iPSCs. 
iPSCs were introduced by the forced expression 
of a set of transcription factors (Oct4, Sox2, Klf4, 
and c-Myc genes) using a retroviral vector in 
somatic cells. These pluripotent reprogrammed 
cells were called iPSCs. Like ESC lines, iPSCs 
can differentiate into all three cell lineages 
including endoderm, while they have intensive 
proliferation in vitro (32, 33). In other studies, 
researches were focused on alternative ways to 
generate iPSC lines, different from integrative 
viral-mediated strategies, e.g. using excisable 
viral vectors (34), RNA-Sendai virus vectors 
(35), episomal plasmids transfections (36), 
miRNA (37) or mRNA transfections (38) as 
well as using only chemical compounds (39).
There are many studies which show that iPSCs 
can differentiate into HLCs (24, 40-43). These 
generated HLCs had some characteristics of 
human hepatocytes, particularly in morphology 
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and phenotype (44), but regarding functional 
assays and metabolic activity, these cells 
were similar to immature hepatocytes (44, 
45). Therefore, numbers of research group 
have been trying to increase the efficiency of 
differentiation of iPSCs to HLCs in 2D and 3D 
with different differentiation protocols (9, 24, 
40, 46, 47). In both 2D and 3D differentiation 
protocols, the extracellular matrix, additional 
cell-cell interactions, the media and 
supplements, i.e. growth factors and cytokines, 
ensure the successful differentiation of iPSCs 
to HLCs (48). Recently, it has been shown that 
in 3D culture, the maturity of HLCs derived 
from iPSCs was increased (46). Moreover, 
spatially patterning of the cells, known as 
self- organization, to give rise to "organoid 
structures" has been introduced in 3D cultures 
(49). These structures can be expanded without 
limiting, cryopreserved as biobanks and easily 
manipulated using techniques established for 
2D culture (50). Takebe et al. (29) in 2013 
demonstrated when human iPSCs were co-
cultured with endothelial and mesenchymal 
cells, they were self-organized in vitro into 
structures like small liver organoids, also called 
"liver buds", while they could be transplanted. 
Moreover, in other studies, researchers have 
tried to manipulate current protocols for more 
hepatocyte maturity, including drug metabolism 
activity (51).
Gestational stem cell-derived hepatocytes 
Another source of HLCs is gestational stem 
cells derived from umbilical cord, umbilical 
cord blood, placenta, and amniotic fluid. This 
type of stem cells, which is easily accessible, can 
generate other cell lineages in vitro and in vivo 
(52, 53). Studies showed that human umbilical 
cord stem cells could differentiate into HLCs 
in vitro, with hepatocyte-like morphology 
and high-level expression of hepatic lineage 
markers. These cells could differentiate into 
HLCs in vivo either after injection into the 
NOD-SCID mice with induced liver damage 
(54, 55). In addition, human placenta-derived 
multipotent cells can also differentiate into 
other cell types including HLCs with primary 
hepatocyte characteristics (56). Gestational stem 
cells do not form teratomas or teratocarcinomas 
in humans, while they have a high proliferation 
rate and differentiation potential. Because of the 
plasticity and accessibility of these stem cells, 
many cord blood banks have been established 
for the collection and storage of these cells for 
future applications (57).
Mesenchymal stromal cells derived hepatocytes
Generation of HLCs from mesenchymal 
stromal cells (MSCs) using different sources 
such as bone marrow (BM-MSCs), umbilical 
cord blood (UC-MSCs), stem cell-derived 
(ESC-MSCs) and adipose tissue MSCs (Ad-
MSCs) have been previously described (58). 
These types of stem cells are fibroblast-
like, plastic-adherent and multipotent cells, 
rapidly expanding in vitro under standard 
conditions. MSCs have low immunogenicity 
and possess immunomodulatory properties, so 
they are commonly used in cirrhosis (59-63). 
They can differentiate into HLCs, expressing 
particular hepatic genes and presenting some 
metabolic activities (64). Culturing BM-MSCs 
in hepatocyte-conditioned medium without 
any growth factors can induce hepatic cell 
differentiation (65). Combination of HGF, 
nicotinamide and dexamethasone in MSCs 
culture medium could induce hepatic fate in 
MSCs (66). Moreover, other growth factors 
like insulin-like growth factor-I in combination 
with liver specific factors have been reported to 
differentiate MSCs into HLCs (67). 
Direct cell conversion to hepatocyte-like cells 
Direct conversion of adult cells like fibroblasts 
to other mature or progenitor somatic cells is an 
alternative way to bypass the pluripotent iPSC 
step, mainly by ectopic expression of particular 
cell-specific transcription factors (TFs). In this 
regard, functional cells are directly generated, 
which are useful in advanced clinical applications 
as well as basic science studies (68, 69). By this 
new method, known as "transdifferentiation", 
different research groups successfully 
converted mouse and human fibroblasts to other 
lineages, including neurons, cardiomyocytes 
and hepatocytes, the latter one was also called 
induced hepatocytes (iHeps). Sekiya and Suzuki 
(70) showed that a combination of Hnf4a with 
Foxa1, Foxa2 or Foxa3 could convert mouse 
adult fibroblasts into iHeps and this generated 
cells could repopulate and save the genetically 
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modified mice model, with deficiency in the 
fumarylacetoacetate hydrolase (Fah) activity, 
leading to the accumulation of metabolites of 
tyrosine that are toxic to native hepatocytes.
In another study, fibroblasts were converted 
to iHeps by the transduction of Hnf1a plus 
Gata4 and Foxa3, and inactivation of p19Arf. 
This iHeps could repopulate the livers of Fah-
/- mice, increasing the survival rate in the 
recipients (71). Similar technique was used to 
generate human induced hepatocyte (hiHeps) 
by the forced expression of HNF1α, HNF4α, 
and HNF6 with ATF5, PROX1, C/EBPβ as the 
maturation factors and P53-shRNA (72). In 
another study by increasing the expression of 
FOXA3, HNF1α, HNF4α and FOXA2, iHeps 
were generated (73). In both studies, in vitro 
gene expression profiles of hiHeps were similar 
to mature human hepatocytes and they showed 
in vivo functionality in FRG (Fah-/-/Rag2-
/-/Il2rg) mouse model. In another strategy, 
Yamanaka factors were used for generation of 
an epigenetic instability, along with the small 
molecules and/or a cocktail of Hnf4a, Cebpa 
and Nr1i2 under hepatic inducing conditions 
(74). In addition, it has been shown that Kdm2b 
as an epigenetic modulator with HNF4α and 
Foxa3 could accelerate generation of iHeps in 
hepatic media (75).
Applications of in vitro produced hepatocyte-like 
cells 
Applications of hepatocyte-like cells in cell therapy 
of acquired liver diseases
There are many patients suffering from liver 
disease worldwide. Many of these patients with 
acquired liver diseases, such as acute liver 
failures (ALF), fulminant hepatic failure and 
chronic liver diseases can benefit from cell 
therapy, specially hepatocyte transplantation 
(2, 76). In acute liver failure and fulminant 
hepatic failure, liver metabolic functions are 
seriously deteriorated following the loss of 
hepatocytes mass caused by toxins, drugs and 
hepatotrophic viruses. In chronic liver diseases, 
severe alteration of hepatic microarchitecture is 
followed by generation of fibrotic areas (77). 
Recently fibrosis regression was reported by in 
vivo hepatocyte transplantation. In these studies 
myofibroblasts, recruited in fibrotic areas, were 
reprogrammed into hepatocytes (78, 79).
Up to now many clinical trials with hepatocyte 
transplantation have been successfully 
performed with cost effeciecy and simply doing 
cell administration by intravascular injection 
rather than surgery (1, 4, 80-84). Moreover, it 
is possible to use cryopreserved hepatocytes 
and may even be transplanted them repeatedly 
(85). Due to the limitations for cell therapy 
with hepatocyte, such as insufficient numbers 
and low viability of cells, in vitro generated 
HLCs offer a new arena for basic studies and 
a potential source for possible use in therapy in 
the future (6, 14). 
Human iPSCs derived hepatocyte-like cells 
(iPSCs-HLCs) presented a new platform for 
the liver cell therapy, but there is no registered 
clinical trial using these cells for cell therapy 
(86). However, in a mouse model it has been 
shown that iPSCs-HLCs could efficiently be 
engraftd into the liver with normal function 
(40). These cells were applied in lethal 
fulminant hepatic failure in non-obese diabetic 
severe combined immunodeficient mice and 
rescued them after cell therapy (87). Because 
of the ethical advantages of iPSCs and using 
autologous starting cells, as an important step 
toward "personalized medicine", it seems 
that iPSCs-HLCs have potential of clinical 
applications in future of liver diseases (6, 88). 
Recently, iPSCs have been generated without 
viral vectors and transgene-free sequences 
by non-integrating episomal vectors (36). 
Transdifferentiation of MSCs into HLCs has 
already been reported and these generated 
HLCs has been characterized in vitro and in 
vivo (58). Animal model studies showed that in 
vitro pre-differentiated MSCs could boost liver 
repopulation and functionality of hepatic cells 
(58, 89). Moreover, co-transplantation of iPSCs-
HLCs and MSCs could be a suitable option for 
the treatment of end-stage liver disease, due 
to the paracrine effects of drived MSC trophic 
factors (76). In Table 1, current cell sources 
for liver cell therapy, as well as some HLCs 
from various sources, as potential cell types 
appropriate for cell therapy, are described. 
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Table 1: Cell therapy of various liver disease with potential pluripotent stem cells-derived HLCs and other appropriate cells
Cell sources Role in disease types Clinical trial Disadvantage Reference
Hepatocytes Metabolic liver disorder
Liver disorders in infants
Autoimmune liver disorders
Yes Possibility of infection 
with hepatitis viruses
Decreased engraftment
ability in injured liver
Limited access
(90)
hESCs-HLCs Liver disorders
Metabolic liver disorder
No Unknown maintenance in 
long-term
(91)
hiPSCs-HLCs Liver disorders
Metabolic liver disorder
No No fully function 
Unknown maintenance in 
long-term
(92)
MSCs Liver disorders
Cirrhosis
There are numbers 
of clinical reports
Some negative results in 
clinical studies
(93)
HLC; Hepatocyte-like cells, hESCs; Human embryonic stem cells, hiPSCs; Human induced pluripotent stem cells, and MSCs; Mesenchymal 
stem cells.
Challenges in cell therapy with hepatocyte-like cells
The ESCs/ iPSCs derived HLCs with current 
protocols have a fetal-like phenotype, rather than 
a mature hepatocyte phenotype, however, it is 
possible to induce more maturation in vivo (45). 
Heterogeneous populations of HLCs, including 
differentiated and undifferentiated cells may 
increase the risk of tumorogenicity due to the high 
proliferation capacity of undifferentiated cells 
(94, 95). Then enrichment strategies create a new 
platform for generating HLCs for future clinical 
and pharmaceutical application (9). Furthermore, 
for any potential clinical use of HLCs derived 
from pluripotent cells, the iPSCs and ESCs 
should be generated in  good manufacturing 
practice (GMP) condition as an appropriate 
system for protection of products and control 
them according to accridated quality standards. 
Therefore, many research groups are working to 
improve the protocol for generating HLCs from 
these pluripotent cells. Up to now, some studies 
showed that transplantation of ESC-derived HLCs 
in animal models could improve hepatic function 
(19, 96-101), but ethical concerns and regulatory 
issues, immunologic rejection and tumorogenicity 
are still the main limiting factors. To avoid time 
consuming procedure in the generation of HLCs 
from pluripotent stem cells under monolayer 
culture, we need to produce HLCs in 3D suspension 
culture for the clinical applications (102). Vosough 
et al. (9) described a scalable stirred-suspension 
bioreactor culture of functional HLCs from the 
hPSCs. After intrasplenic transplantation of these 
HLCs in acute liver injury, an increased survival 
rate and efficient engraftment of functional cells 
were observed.
Applications of hepatocyte-like cells in cell therapy 
of acquired liver diseases
iPSC technology provides the possibility of 
"gene correction" on patient somatic cells. The 
gene correction on iPSCs can be applied for 
patients with monogenic inherited metabolic liver 
diseases, like Alpha-1 antitrypsin deficiency and 
Wilson’s disease (mutation in ATP7B gene). After 
ex vivo gene correction, iPSCs can differentiate into 
hepatocyte and then be transplanted to the patient 
(76). In gene correction of Alpha-1 antitrypsin 
deficiency in iPSCs, scientists showed that a 
combination of two targeted gene technologies, 
zinc finger nucleases (ZFNs) and PiggyBac (PB) 
technology, which were significantly efficient 
gene-targeting technology, could correct a point 
mutation (Glu342Lys) and then corrected iPSCs-
HLCs could restore the structure and function in 
vitro and in vivo (103). In another study, researchers 
tried to generate iPSCs from a Chinese patient 
with Wilson’s disease (WD) that bears the R778L 
Chinese hotspot mutation in the ATPase Cu2+ 
transporting beta polypeptide (ATP7B) gene. 
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After gene correction using a self-inactivating 
lentiviral vector that expresses codon-optimized 
ATP7B, these iPSCs were differentiated into 
HLCs with copper metabolism capacity, which 
reversed the functional defect in vitro. These 
studies could introduce a new way for generating 
disease modeling valuable for screening alleviate 
compounds or gene therapy approaches (104).
Recently, some new technologies such as 
clustered regularly interspaced short palindromic 
repeats (CRISPR)/Cas based RNA-guided DNA 
endonucleases , as a new and powerful genome 
editing tool, allow precise gene editing in liver-
based monogenic disorders in animal models by 
either permanently deleting/inserting specific 
genetic sequences or adding/removing epigenetic 
information temporarily with minimal off-target 
modifications (105, 106).  In a new study, researchers 
used dual adeno-associated virus (AAV) vectors 
to deliver the CRISPR/Cas9 components, one 
expressing Cas9 and the other expressing a guide 
RNA as well as the donor DNA, to newborn mice 
with a partial deficiency in the urea cycle disorder 
enzyme, ornithine transcarbamylase (OTC), 
which resulted in improvment of their survival 
rate. They limited any off-target activity by using 
a liver-specific promoter for Cas9, ensuring its 
expression only within liver cells (107). In another 
study, viral and non-viral delivery systems were 
used. So, gene editing was accomplished with 
a combination of lipid nanoparticle–mediated 
delivery of Cas9 mRNA with adeno-associated 
viruses encoding a sgRNA and a repair template, 
to induce repair of a human hereditary tyrosinemia 
disease gene in adult mouse models. In this report, 
disease symptoms, such as weight loss and liver 
damage, were rescued. In addition, the efficiency 
of correction was reported less than 6% of 
hepatocytes after a single application (108). These 
presented results and efficacy of corrections were 
suggested potential utility of CRISPR-mediated 
gene repair for genetic diseases.
Applications of hepatocyte-like cells in cell therapy 
of acquired liver diseases
HLCs, obtained from various sources, have 
cytochrome P450 (CYPs) activity, which is crucial 
for metabolism of xenobiotics and drugs (Table 
2) (45, 73, 109). Although one of the main goal 
of improving differentiation protocols in different 
studies is increasing the functionality of generating 
cells in drug metabolism and appropriate CYPs 
activity. Recent studies tried to show an increasing 
activity of HLCs in drug metabolism (51, 72, 
109). To measure the capability of HLCs for drug 
metabolism, particular substances were introduced, 
including phenacetin (CYP1A), bupropion 
(CYP2B6), diclofenac (CYP2C9) and midazolam 
(CYP3A) (109). Before evaluating the HLCs, they 
should be treated with an appropriate inducer, like 
phenobarbital and rifampicin. In addition, mRNA 
and protein expression of important CYPs in the 
presence and absence of inducers can be checked 
in HLCs (70, 109-112).
If researchers can generate HLCs with the 
ability of drug metabolism, these cells might 
be replaced with primary hepatocyte as a 
"gold standard" for drug metabolism and drug 
toxicity tests (86). Activity and expression of 
drug transporters are another characteristic that 
sometimes were assessed in generating HLCs in 
various studies to evaluate the quality of them 
compared to primary hepatocytes. Therefore 
the activity of the uptake transporters such 
as organic anion transporting polypeptides 
(OATPs), OATP1B1 and Na(+)-taurocholate co-
transporting polypeptide (NTCP) as well as the 
efflux transporter bile salt export pump (BSEP) 
were evaluated (109).
Another important application of HLCs, 
especially with iPSC technology, is in discovery 
of new and safe drugs, small molecules and 
components to alleviate the respective property 
after high-throughput screening. In this way, 
HLCs produced by patient specific iPSCs were 
checked by the array of drugs or components to 
find new drugs or investigating toxicity of drugs. 
Moreover, testing drugs for iPSC that belong to 
an individual, admirably help to choose the best 
drug among various candidates and also determine 
the best dose of the chosen drug for every patient 
(14, 86, 113). Undoubtedly, this is the best way 
for "personalized drug administration" which will 
guide toward the future medicine. In addition, 
recently bioengineering tools such as microfluidic-
based cell culture device opened new window to 
drug studies with HLCs (114). This controlled 
system allows exact spatial and frequent delivery 
of media, drugs and signaling factors to live cells 
(115). Giobbe et al. (116) reported a microfluidic 
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system on the chip to differentiate PSCs into HLCs 
to predict drug toxicity. Further more, by providing 
a controlled microenvironment for generating 
HLCs, microfluidic systems make it feasible 
to study the candidate or new drug metabolism 
and drug-response screening in high-throughput 
testing (117, 118).
Recent developments in humanized liver 
models present a promising horizon in the future 
preclinical applications of generated hepatocytes 
in vivo, especially for drug discovery (3). It has 
been reported that human hepatocyte can be 
transplanted into the animal models and they can 
be repopulated in the host liver (119). Highly 
immunodeficient FRG [Fah(-/-) Rag2(-/-) Il2rg (-/-)] 
mice are currently the best model for repopulation 
of human hepatocyte in animals. This model is T, B 
and NK cells deficient, in addition to deficiency in 
the fumarylacetoacetate hydrolase (Fah) activity, 
as an enzyme catalyzing the last step of tyrosine 
metabolism (120). Researchers reported that FRG 
mice liver can be repopulated efficiently with 
human hepatocyte and display a serum lipoprotein 
profile similar to human apolipoproteins.
Table 2: Examples of recently reported CYP enzymes activity and drug metabolisms in generated HLCs from different sources
Cell sources CYP enzymes/Drug 
metabolism
Method of analysis Inducer Reference
hESC CYP1A1, CYP1A2, CYP3A4, 
CYP7A1, CYP1B1, CYP2B6, 
CYP2C9,CYP2C19, CYP2D6, 
CYP2E1
PCR No (121)
hESC, hiPSC CYP1A2, CYP3A4, CYP3A7, 
CYP2D6, CYP2C9, CYP2C19
Immunohistochemistry/ 
luminescence based kit
Phenobarbital, rifampicin 
and acetaminophen
(122)
iPSCs CYP3A4 luminescence based kit No (46)
iPSCs CYP1A1 EROD Ethoxyresorufin, dicumarol (123)
Fibroblast (direct 
conversion)
CYP1A2, CYP2B6, CYP2C9, 
CYP2C19, CYP3A4, CYP2C9, 
CYP2C19, CYP1A2, CYP3A4
Testosterone, midazolam, 
phenacetin, bupropion, 
diclofenac, S-mephenytoin
qPCR, IF,
HPLC-MS
Rifampicin, 
b-naphthoflavone, 
phenobarbital
(72)
Fibroblast (direct 
conversion)
CYP1A2, CYP2A6, CYP2B6, 
CYP2C8, CYP2C9, CYP3A4/
phenacetin, coumarin, 
dextromethorphan
qPCR,
LC-MS/MS
3-methylcholanthrene,
phenobarbital, or 
rifampicin
(73)
AT-MSC CYP1A1, CYP1A2, CYP2A1, 
CYP2C7, CYP2C12, CYP2E1, 
CYP3A1
Phenacetin, coumarin, 
chlorzoxazone
qPCR,
LC-MS/MS
No inducer,
3-methylcholanthrene, 
phenobarbital,
and acetone
(124)
Human umbilical 
cord-derived MSC
CYP3A4 Liquid chromatography Midazolam (125)
HLCs; Hepatocyte-like cells, hESC; Human emberyonic stem cell, iPSCs; Induced pluripotent stem cells, AT-MSC; Adipose-derived 
mesenchymal stem cells, qPCR; Quantitative polymerase chain reaction, IF; Immunofluorescence, HPLC-MS; Liquid chromatography-
mass spectrometry, and LC-MS/MS; Liquid chromatography tandem-mass spectrometry.
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They displayed that these humanized FRG 
mice have capacity to be a suitable model for 
atherosclerosis and cholesterol metabolism. 
Moreover and interestingly, in these mice drug 
metabolizing enzyme system were humanized 
either (126). Hickey et al. (127) represented a 
new Fah(-/-) pigs, as a large animal model. Fah 
deficiency is an utero lethal difficulty in pigs that 
is correctable with administration of 2-(2-nitro-
4-trifluoromethylbenzoyl)-1,3 cyclohexanedione 
(NTBC). After withdrawing NTBC, FAH−/− pigs 
died due to acute liver failure. This animal model 
may be suitable platform to generate HLCs with 
further functionality. Another research group tried 
to improve repopulation efficacy of humanized 
liver in chimeric mice with transduction of HLCs 
by adenovirus vector (Ad-FNK) to express FNK. 
Overexpression of FNK resulted in apoptosis 
inhibition in HLCs. In this study, Ad-FNK-
transduced human iPSC-HLCs transplanted into 
urokinase-type plasminogen activator-transgenic 
severe combined immunodeficiency (uPA/SCID) 
mice and assessed the effectiveness of repopulation. 
Human albumin levels, human hepatocyte-related 
genes and proteins in the transplanted mice were 
significantly increased in this model (128). Briefly, 
human pluripotent stem cell-derived HLCs 
are appropriate and promising sources for the 
generation of humanized liver models.
Achieving adequate and appropriate HLCs, 
is an important route for cell therapy of patients 
with end-stage liver failure (48). There are some 
potential sources that researchers have focused on 
it in recent years for obtaining functional HLCs, 
including mainly stem cells-based sources like 
MSCs, pluripotent stem cells, hESC and induced 
pluripotent stem cell (iPSC) lines, as well as 
direct lineage conversion of adult somatic cells 
to HLCs as a new strategy (129). HLCs exhibit 
many phenotypes and some functional traits of 
mature hepatocytes (6). Up to now there is no 
registered clinical trial using HLCs, but there 
are some considerable potential advantages of 
HLCs against primary hepatocytes, especially 
for iPSC-HLCs, including potential of large scale 
production, patient-specificity of iPSC-HLCs 
preventing transplanted cell immunorejection, 
possibility of gene editing of autologous iPSC-
HLCs with non-integrated tools to treat inherited 
genetic liver diseases prior to differentiation and 
transplantation, especially with helping new tools 
such as the most widely used engineered CRISPR/
Cas system (77, 107, 108). The CRISPR/Cas9 
method, as a powerful genome editing system, 
successfully corrected point mutations in A1AT 
deficiency disease-specific iPSCs (105). Moreover, 
PCSK9 gene was mutated by CRISPR/Cas9 
system in mouse liver for changing the lipid profile 
of animals, i.e. decreasing plasma cholesterol level 
and increasing LDL receptors (130). In another 
study, an adenovirus based CRISPR/Cas9 system 
for in vivo gene editing precisely knocked-out the 
CEBPα gene, as an important transcription factor 
for metabolic genes in the liver organ (131).
Various studies have confirmed the feasibility of 
generating and cultivating human pluripotent stem 
cells in stirred suspension bioreactors (9, 132). 
Using this technology helped us to move forward 
to practical applications, requiring a large number 
of cells for treatment and high- throughput drug 
screening (48).
HLCs have been shown to be a powerful in 
vitro system not only to study patient-specific 
disease model and some human liver disease, i.e. 
viral hepatitis and plasmodium infection (133-
136), but also to drug study, especially with the 
help of modern techniques such as microfluidic-
based cell culture platforms. This system either 
allows to improve HLCs generation by providing 
monitoring of culture parameters or helping to 
co-culture of HLCs with the other cells, even 
from other organs, make it possible to investigate 
unintended systemic side-effects of therapeutic 
agents and their metabolites (137). Moreover, 
human pluripotent stem cells-derived HLCs 
provide infinite and genetically defined sources for 
humanized liver models. These animal models will 
provide many in vitro applications, including high-
throughput drug screening, toxicology and further 
applications in liver assist devices (138).
Finding potential sources and strategies for 
generating HLCs open a new window in liver 
regenerative medicine, but many considerable 
experimental challenges remain to be solved 
including finding new methods or biomolecules 
improving the efficiency as well as extending 
differentiation of these cells and metabolic 
activity of generated HLCs. Besides, finding new 
improved methods to enrich, purify and large-scale 
production of HLCs are necessary. On the other 
hand, development of suitable animal models 
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and efficient HLCs delivery strategies should be 
considered for improvement of future clinical use 
(139).
Conclusion
In vitro generation of HLCs using pluripotent or 
non-pluripotent cells via differentiation and direct 
conversion to hepatocytes provides potential 
applications in regenerative medicine, via cell 
and gene therapies for liver diseases and drug 
discovery. At this time, considerable experiments 
continue to increase the functionality of generated 
HLCs to introduce them as a suitable replacement 
for primary hepatocytes.
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